Pharmaceutical

Alzheimer’s R&D resurgence driven by $16.8bn in acquisitions in 2025YTD

Acquisitions involving innovator drugs have grown year-on-year with total deal value increasing eight-fold to almost $18 billion in 2024.

Jun 25, 2025 - 06:00
Alzheimer’s R&D resurgence driven by $16.8bn in acquisitions in 2025YTD
Acquisitions involving innovator drugs have grown year-on-year with total deal value increasing eight-fold to almost $18 billion in 2024.
Read the original article

Tags:

Previous Article

Revolutionizing π-Molecules: A Novel Design Strategy Transforms Organic Semicond...

Next Article

Revolution Medicines partners Royalty Pharma on $2bn funding

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

What’s next for AAV gene therapies in 2024?

What’s next for AAV gene therapies in 2024?

Mar 11, 2024

Over half of world’s population not covered by essential healthcare services

Over half of world’s population not covered by essentia...

Sep 23, 2023

STAT+: ‘Are we better off with the information?’: Experts spar over the benefits of liquid biopsy to catch cancer

STAT+: ‘Are we better off with the information?’: Exper...

May 7, 2023